{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:11:55Z","timestamp":1785521515750,"version":"3.56.0"},"reference-count":143,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["13-15008S"],"award-info":[{"award-number":["13-15008S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,3,14]]},"abstract":"<jats:sec><jats:title\/><jats:p>Heart is a particularly sensitive organ to iron overload and cardiomyopathy due to the excessive cardiac iron deposition causes most deaths in disorders such as beta-thalassemia major. Free or loosely bound iron ions readily cycle between ferrous and ferric states and catalyze Haber-Weiss reaction that yields highly reactive and toxic hydroxyl radicals. Treatment with iron chelators (desferrioxamine, deferiprone, and deferasirox) substantially improved cardiovascular morbidity and mortality in iron overloaded patients. Furthermore, iron chelators have been studied in various cardiovascular disorders with known or presumed oxidative stress roles (e.g., ischemia\/reperfusion injury) also in patients with normal body iron contents. The pharmacodynamic and pharmacokinetic properties of these chelators are critical for effective therapy. For example, the widely clinically used but hydrophilic chelator desferrioxamine suffers from poor plasma membrane permeability, which means that high and clinically unachievable concentrations\/doses must be employed to obtain cardioprotection. Therefore, small-molecular and lipophilic chelators with oral availability are more suitable for this purpose, particularly in states without systemic iron overload. Apart from agents that are already used in clinical practice, aroylhydrazone iron chelators, namely salicylaldehyde isonicotinoyl hydrazone (SIH), have provided promising results. However, the use of classical iron-chelating agents is associated with a risk of toxicity due to indiscriminate iron depletion. Recent studies have therefore focused on &amp;quot;masked&amp;quot; prochelators that have little or no affinity for iron until site-specific activation by reactive oxygen species.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867324666170920155439","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T09:23:51Z","timestamp":1552555431000},"page":"288-301","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cardioprotective Potential of Iron Chelators and Prochelators"],"prefix":"10.2174","volume":"26","author":[{"given":"Hana","family":"Jansov\u00e1","sequence":"first","affiliation":[{"name":"Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u015b","family":"\u0160im\u016fnek","sequence":"additional","affiliation":[{"name":"Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0891-5849(02)01006-7","volume":"33","author":"Kakhlon O.","year":"2002","unstructured":"Kakhlon O, Cabantchik ZI. The labile iron pool: Characterization, measurement, and participation in cellular processes.","journal-title":"Free Radic Biol Med"},{"key":"ref=2","doi-asserted-by":"crossref","DOI":"10.1002\/0470845791","author":"Crichton R.","year":"2001","unstructured":"Crichton R, Boelaert JR, Braun V, Hantke K, Marx JJM, Santos M, Ward R.","journal-title":"Inorg Biochem Iron Metab"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1042\/BST0351147","volume":"35","author":"Halliwell B.","year":"2007","unstructured":"Halliwell B. Biochemistry of oxidative stress.","journal-title":"Biochem Soc Trans"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tox.2011.03.001","volume":"283","author":"Jomova K.","year":"2011","unstructured":"Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease.","journal-title":"Toxicology"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1358836X9900400207","volume":"4","author":"Horwitz L.D.","year":"1999","unstructured":"Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury.","journal-title":"Vasc Med"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gut.51.2.290","volume":"51","author":"Trinder D.","year":"2002","unstructured":"Trinder D, Fox C, Vautier G, Olynyk JK. Molecular pathogenesis of iron overload.","journal-title":"Gut"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.111.050773","volume":"124","author":"Kremastinos D.T.","year":"2011","unstructured":"Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice.","journal-title":"Circulation"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.111.059477","volume":"125","author":"Weidemann F.","year":"2012","unstructured":"Weidemann F, Rummey C, Bijnens B, Stork S, Jasaityte R, Dhooge J, Baltabaeva A, Sutherland G, Schulz JB, Meier T. Mitochondrial Protection With Idebenone In Cardiac Or Neurological Outcome Study, G. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms.","journal-title":"Circulation"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4330\/wjc.v3.i6.186","volume":"3","author":"Perrelli M.G.","year":"2011","unstructured":"Perrelli MG, Pagliaro P, Penna C. Ischemia\/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species.","journal-title":"World J Cardiol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/0022-2828(95)90041-1","volume":"27","author":"Horwitz L.D.","year":"1995","unstructured":"Horwitz LD, Leff JA. Catalase and hydrogen peroxide cytotoxicity in cultured cardiac myocytes.","journal-title":"J Mol Cell Cardiol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0891-5849(92)90091-T","volume":"12","author":"Reif D.W.","year":"1992","unstructured":"Reif DW. Ferritin as a source of iron for oxidative damage.","journal-title":"Free Radic Biol Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/10715760500511484","volume":"40","author":"Mladenka P.","year":"2006","unstructured":"Mladenka P, Simunek T, Hubl M, Hrdina R. The role of reactive oxygen and nitrogen species in cellular iron metabolism.","journal-title":"Free Radic Res"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1161\/01.CIR.96.10.3300","volume":"96","author":"Kiechl S.","year":"1997","unstructured":"Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study.","journal-title":"Circulation"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.33549\/physiolres.933589","volume":"66","author":"Kraml P.","year":"2017","unstructured":"Kraml P. The role of iron in the pathogenesis of atherosclerosis.","journal-title":"Physiol Res"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","volume":"61","author":"Simunek T.","year":"2009","unstructured":"Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron.","journal-title":"Pharmacol Rep"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.14712\/18059694.2019.117","volume":"43","author":"Hrdina R.","year":"2000","unstructured":"Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M. Anthracycline-induced cardiotoxicity.","journal-title":"Acta Med (Hradec Kralove)"},{"key":"ref=17","first-page":"245","volume":"122","author":"Hershko C.","year":"1993","unstructured":"Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, Pinson A. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: Studies in rat heart cells in culture.","journal-title":"J Lab Clin Med"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/cncr.28256","volume":"119","author":"Lipshultz S.E.","year":"2013","unstructured":"Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.","journal-title":"Cancer"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.85.2.790","volume":"85","author":"Mann D.L.","year":"1992","unstructured":"Mann DL, Kent RL, Parsons B, Cooper G. m 4. Adrenergic effects on the biology of the adult mammalian cardiocyte.","journal-title":"Circulation"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1472-8206.2010.00836.x","volume":"24","author":"Dhalla N.S.","year":"2010","unstructured":"Dhalla NS, Adameova A, Kaur M. Role of catecholamine oxidation in sudden cardiac death.","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-444-63600-3.00004-0","volume":"140","author":"Osteraas N.D.","year":"2017","unstructured":"Osteraas ND, Lee VH. Neurocardiology.","journal-title":"Handb Clin Neurol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2174\/092986711795656081","volume":"18","author":"Costa V.M.","year":"2011","unstructured":"Costa VM, Carvalho F, Bastos ML, Carvalho RA, Carvalho M, Remiao F. Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases.","journal-title":"Curr Med Chem"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.freeradbiomed.2010.12.004","volume":"50","author":"Ha\u0161kov\u00e1 P.","year":"2011","unstructured":"Ha\u0161kov\u00e1 P, Kova\u0159\u00edkov\u00e1 P, Koubkov\u00e1 L, V\u00e1vrov\u00e1 A, Mackov\u00e1 E, Sim\u016fnek T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.","journal-title":"Free Radic Biol Med"},{"key":"ref=24","unstructured":"14-34."},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1389557013406846","volume":"1","author":"Galey J.B.","year":"2001","unstructured":"Galey JB. Recent advances in the design of iron chelators against oxidative damage.","journal-title":"Mini Rev Med Chem"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1196\/annals.1345.006","volume":"1054","author":"Borgna-Pignatti C.","year":"2005","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A. Survival and complications in thalassemia.","journal-title":"Ann N Y Acad Sci"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/0929867033457638","volume":"10","author":"Buss J.L.","year":"2003","unstructured":"Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy.","journal-title":"Curr Med Chem"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/mol.109.061028","volume":"77","author":"Saletta F.","year":"2010","unstructured":"Saletta F, Suryo Rahmanto Y, Noulsri E, Richardson DR. Iron chelator-mediated alterations in gene expression: Identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53.","journal-title":"Mol Pharmacol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1386-6532(00)00122-0","volume":"20","author":"van Asbeck B.S.","year":"2001","unstructured":"van Asbeck BS, Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ. Anti-HIV effect of iron chelators: Different mechanisms involved.","journal-title":"J Clin Virol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/138920010791196265","volume":"11","author":"Reelfs O.","year":"2010","unstructured":"Reelfs O, Eggleston IM, Pourzand C. Skin protection against UVA-induced iron damage by multiantioxidants and iron chelating drugs\/prodrugs.","journal-title":"Curr Drug Metab"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/01.CIR.103.23.2799","volume":"103","author":"Duffy S.J.","year":"2001","unstructured":"Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Vita JA. Iron chelation improves endothelial function in patients with coronary artery disease.","journal-title":"Circulation"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.parkreldis.2011.06.024","volume":"18","author":"Kwiatkowski A.","year":"2012","unstructured":"Kwiatkowski A, Ryckewaert G, Jissendi Tchofo P, Moreau C, Vuillaume I, Chinnery PF, Destee A, Defebvre L, Devos D. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation.","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lfs.2015.06.026","volume":"136","author":"Salkovic-Petrisic M.","year":"2015","unstructured":"Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smailovic U, Trkulja V, Riederer P, Amit T, Mandel S, Youdim MB. Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer\u2019s disease.","journal-title":"Life Sci"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jtemb.2014.12.012","volume":"31","author":"Ward R.J.","year":"2015","unstructured":"Ward RJ, Dexter DT, Crichton RR. Neurodegenerative diseases and therapeutic strategies using iron chelators.","journal-title":"J Trace Elem Med Biol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/CIRCINTERVENTIONS.111.966226","volume":"5","author":"Chan W.","year":"2012","unstructured":"Chan W, Taylor AJ, Ellims AH, Lefkovits L, Wong C, Kingwell BA, Natoli A, Croft KD, Mori T, Kaye DM, Dart AM, Duffy SJ. Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction.","journal-title":"Circ Cardiovasc Interv"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1139\/y2012-096","volume":"90","author":"Neckar J.","year":"2012","unstructured":"Neckar J, Boudikova A, Mandikova P, Sterba M, Popelova O, Miksik I, Dabrowska L, Mraz J, Gersl V, Kolar F. Protective effects of dexrazoxane against acute ischaemia\/reperfusion injury of rat hearts.","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/asheducation-2011.1.451","volume":"2011","author":"Kwiatkowski J.L.","year":"2011","unstructured":"Kwiatkowski JL. Real-world use of iron chelators.","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"107","author":"Pennell D.J.","year":"2006","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.","journal-title":"Blood"},{"key":"ref=39","first-page":"1241","volume":"91","author":"Galanello R.","year":"2006","unstructured":"Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.","journal-title":"Haematologica"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","volume":"355","author":"Modell B.","year":"2000","unstructured":"Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register.","journal-title":"Lancet"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bcmd.2011.07.002","volume":"47","author":"Maggio A.","year":"2011","unstructured":"Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassara F, Harmatz P, Wood J, Gluud C. Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials.","journal-title":"Blood Cells Mol Dis"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.RES.63.2.351","volume":"63","author":"Farber N.E.","year":"1988","unstructured":"Farber NE, Vercellotti GM, Jacob HS, Pieper GM, Gross GJ. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart.","journal-title":"Circ Res"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12265-015-9633-5","volume":"8","author":"Phaelante A.","year":"2015","unstructured":"Phaelante A, Rohde LE, Lopes A, Olsen V, Tobar SA, Cohen C, Martinelli N, Biolo A, Dal-Pizzol F, Clausell N, Andrades M. N-acetylcysteine plus deferoxamine improves cardiac function in wistar rats after non-reperfused acute myocardial infarction.","journal-title":"J Cardiovasc Transl Res"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"H2889","DOI":"10.1152\/ajpheart.2000.279.6.H2889","volume":"279","author":"Ryter S.W.","year":"2000","unstructured":"Ryter SW, Si M, Lai CC, Su CY. Regulation of endothelial heme oxygenase activity during hypoxia is dependent on chelatable iron.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/cvr\/25.9.711","volume":"25","author":"Reddy B.R.","year":"1991","unstructured":"Reddy BR, Wynne J, Kloner RA, Przyklenk K. Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury.","journal-title":"Cardiovasc Res"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/tx100125t","volume":"23","author":"Bendova P.","year":"2010","unstructured":"Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR, Simunek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.","journal-title":"Chem Res Toxicol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tox.2011.08.006","volume":"289","author":"Haskova P.","year":"2011","unstructured":"Haskova P, Koubkova L, Vavrova A, Mackova E, Hruskova K, Kovarikova P, Vavrova K, Simunek T. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.","journal-title":"Toxicology"},{"key":"ref=48","first-page":"159","volume":"152","author":"El-Demerdash E.","year":"2004","unstructured":"El-Demerdash E, Mohamadin AM. Does oxidative stress contribute in tricyclic antidepressants-induced cardiotoxicity?","journal-title":"Toxicol Lett"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0928-4680(02)00054-8","volume":"9","author":"Dobsak P.","year":"2002","unstructured":"Dobsak P, Siegelova J, Wolf JE, Rochette L, Eicher JC, Vasku J, Kuchtickova S, Horky M. Prevention of apoptosis by deferoxamine during 4 hours of cold cardioplegia and reperfusion: study of isolated working rat heart model.","journal-title":"Pathophysiology"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/phrs.2000.0769","volume":"43","author":"Saad S.Y.","year":"2001","unstructured":"Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats.","journal-title":"Pharmacol Res"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1006\/jmcc.1994.1136","volume":"26","author":"Voest E.E.","year":"1994","unstructured":"Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.","journal-title":"J Mol Cell Cardiol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00686629","volume":"35","author":"Herman E.H.","year":"1994","unstructured":"Herman EH, Zhang J, Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.19082\/2425","volume":"8","author":"Hassan M.A.","year":"2016","unstructured":"Hassan MA, Tolba OA. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: A comparative study of deferasirox and deferoxamine.","journal-title":"Electron Physician"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0378-5955(97)00094-4","volume":"112","author":"Ryals B.","year":"1997","unstructured":"Ryals B, Westbrook E, Schacht J. Morphological evidence of ototoxicity of the iron chelator deferoxamine.","journal-title":"Hear Res"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0022-2828(91)90133-7","volume":"23","author":"Beresewicz A.","year":"1991","unstructured":"Beresewicz A, Horackova M. Alterations in electrical and contractile behavior of isolated cardiomyocytes by hydrogen peroxide: Possible ionic mechanisms.","journal-title":"J Mol Cell Cardiol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","volume":"102","author":"Hoffbrand A.V.","year":"2003","unstructured":"Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload.","journal-title":"Blood"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","volume":"360","author":"Anderson L.J.","year":"2002","unstructured":"Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.","journal-title":"Lancet"},{"key":"ref=58","first-page":"489","volume":"88","author":"Piga A.","year":"2003","unstructured":"Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.","journal-title":"Haematologica"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-07-2933","volume":"107","author":"Borgna-Pignatti C.","year":"2006","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.","journal-title":"Blood"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","volume":"115","author":"Tanner M.A.","year":"2007","unstructured":"Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.","journal-title":"Circulation"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/01.CIR.80.1.158","volume":"80","author":"van der Kraaij A.M.","year":"1989","unstructured":"van der Kraaij AM, van Eijk HG, Koster JF. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3.","journal-title":"Circulation"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0891-5849(02)00873-0","volume":"33","author":"Barnabe N.","year":"2002","unstructured":"Barnabe N, Zastre JA, Venkataram S, Hasinoff BB. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.","journal-title":"Free Radic Biol Med"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-2143(96)90095-5","volume":"127","author":"Link G.","year":"1996","unstructured":"Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction.","journal-title":"J Lab Clin Med"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1745-7254.2006.00409.x","volume":"27","author":"Xu L.J.","year":"2006","unstructured":"Xu LJ, Jin L, Pan H, Zhang AZ, Wei G, Li PP, Lu WY. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.","journal-title":"Acta Pharmacol Sin"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/jpet.108.137604","volume":"326","author":"Popelova O.","year":"2008","unstructured":"Popelova O, Sterba M, Simunek T, Mazurova Y, Guncova I, Hroch M, Adamcova M, Gersl V. Deferiprone does not protect against chronic anthracycline cardiotoxicity","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","volume":"102","author":"Cohen A.R.","year":"2003","unstructured":"Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.","journal-title":"Blood"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/0006-2952(93)90222-I","volume":"45","author":"Waldmeier P.C.","year":"1993","unstructured":"Waldmeier PC, Buchle AM, Steulet AF. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain","journal-title":"Biochem Pharmacol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V97.4.1115","volume":"97","author":"Hershko C.","year":"2001","unstructured":"Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.","journal-title":"Blood"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2009-11-250308","volume":"116","author":"Wood J.C.","year":"2010","unstructured":"Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD. The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores.","journal-title":"Blood"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2147\/TCRM.S5497","volume":"5","author":"Taher A.","year":"2009","unstructured":"Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload.","journal-title":"Ther Clin Risk Manag"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2009-04-217455","volume":"115","author":"Pennell D.J.","year":"2010","unstructured":"Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.","journal-title":"Blood"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2006-05-020867","volume":"108","author":"Glickstein H.","year":"2006","unstructured":"Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.","journal-title":"Blood"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ajh.21487","volume":"84","author":"Al-Rousan R.M.","year":"2009","unstructured":"Al-Rousan RM, Paturi S, Laurino JP, Kakarla SK, Gutta AK, Walker EM, Blough ER. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.","journal-title":"Am J Hematol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bcmd.2012.10.006","volume":"50","author":"Lal A.","year":"2013","unstructured":"Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.","journal-title":"Blood Cells Mol Dis"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2014-07-586677","volume":"125","author":"Aydinok Y.","year":"2015","unstructured":"Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, Kilinc Y, Perrotta S, Karakas Z, Viprakasit V, Habr D, Constantinovici N, Shen J, Porter JB. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.","journal-title":"Blood"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.freeradbiomed.2014.06.019","volume":"74","author":"Jansov\u00e1 H.","year":"2014","unstructured":"Jansov\u00e1 H, Mach\u00e1\u010dek M, Wang Q, Ha\u0161kov\u00e1 P, Jirkovsk\u00e1 A, Pot\u016f\u010dkov\u00e1 E, Kielar F, Franz KJ, Sim\u016fnek T. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.","journal-title":"Free Radic Biol Med"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2003.08.005","volume":"35","author":"Hasinoff B.B.","year":"2003","unstructured":"Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.","journal-title":"Free Radic Biol Med"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2012-05-370098","volume":"120","author":"Hoffbrand A.V.","year":"2012","unstructured":"Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload.","journal-title":"Blood"},{"key":"ref=79","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/008922s016lbl.pdf"},{"key":"ref=80","first-page":"204","volume":"55","author":"","year":"2006","unstructured":". CDC Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jacl.2015.09.005","volume":"10","author":"Ibad A.","year":"2016","unstructured":"Ibad A, Khalid R, Thompson PD. Chelation therapy in the treatment of cardiovascular diseases.","journal-title":"J Clin Lipidol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mhj.2000.107549","volume":"140","author":"Lamas G.A.","year":"2000","unstructured":"Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff?","journal-title":"Am Heart J"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1440-1681.1999.03156.x","volume":"26","author":"Green D.J.","year":"1999","unstructured":"Green DJ, O\u2019Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor RR. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jama.287.4.481","volume":"287","author":"Knudtson M.L.","year":"2002","unstructured":"Knudtson ML, Wyse DG, Galbraith PD, Brant R, Hildebrand K, Paterson D, Richardson D, Burkart C, Burgess E. PATCH Investigators. Chelation therapy for ischemic heart disease: A randomized controlled trial.","journal-title":"JAMA"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1067\/mhj.2000.107548","volume":"140","author":"Ernst E.","year":"2000","unstructured":"Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations.","journal-title":"Am Heart J"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11886-015-0656-y","volume":"17","author":"Ouyang P.","year":"2015","unstructured":"Ouyang P, Gottlieb SH, Culotta VL, Navas-Acien A. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.","journal-title":"Curr Cardiol Rep"},{"key":"ref=87","first-page":"22","volume":"24","author":"Wirebaugh S.R.","year":"1990","unstructured":"Wirebaugh SR, Geraets DR. Apparent failure of edetic acid chelation therapy for the treatment of coronary atherosclerosis.","journal-title":"Ann Pharmacother"},{"key":"ref=88","first-page":"24","volume":"19","author":"Shrihari J.S.","year":"2006","unstructured":"Shrihari JS, Roy A, Prabhakaran D, Reddy KS. Role of EDTA chelation therapy in cardiovascular diseases.","journal-title":"Natl Med J India"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2261-5-32","volume":"5","author":"Seely D.M.","year":"2005","unstructured":"Seely DM, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: A systematic review.","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2013.2107","volume":"309","author":"Lamas G.A.","year":"2013","unstructured":"Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: The TACT randomized trial.","journal-title":"JAMA"},{"key":"ref=91","first-page":"627","volume":"40","author":"Guldager B.","year":"1993","unstructured":"Guldager B, Brixen KT, Jorgensen SJ, Nielsen HK, Mosekilde L, Jelnes R. Effects of intravenous EDTA treatment on serum parathyroid hormone (1-84) and biochemical markers of bone turnover.","journal-title":"Dan Med Bull"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2143(98)90180-9","volume":"131","author":"Richardson D.R.","year":"1998","unstructured":"Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease.","journal-title":"J Lab Clin Med"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0167-4889(91)90192-Z","volume":"1091","author":"Richardson D.R.","year":"1991","unstructured":"Richardson DR, Baker E. The release of iron and transferrin from the human melanoma cell.","journal-title":"Biochim Biophys Acta"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01142555","volume":"2","author":"Richardson D.R.","year":"1989","unstructured":"Richardson DR, Hefter GT, May PM, Webb J, Baker E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II).","journal-title":"Biol Met"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0005-2728(97)00008-X","volume":"1320","author":"Richardson D.R.","year":"1997","unstructured":"Richardson DR. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.","journal-title":"Biochim Biophys Acta"},{"key":"ref=96","first-page":"112","volume":"27","author":"Brittenham G.M.","year":"1990","unstructured":"Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration.","journal-title":"Semin Hematol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0304-4165(02)00478-6","volume":"1619","author":"Buss J.L.","year":"2003","unstructured":"Buss JL, Ponka P. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs.","journal-title":"Biochim Biophys Acta"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"9757","DOI":"10.1073\/pnas.0804261105","volume":"105","author":"Whitnall M.","year":"2008","unstructured":"Whitnall M, Suryo Rahmanto Y, Sutak R, Xu X, Becker EM, Mikhael MR, Ponka P, Richardson DR. The MCK mouse heart model of Friedreich\u2019s ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.phrs.2004.08.005","volume":"51","author":"Simunek T.","year":"2005","unstructured":"Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, Hrdina R, Gersl V, Ponka P. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.","journal-title":"Pharmacol Res"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-1-4615-0593-8_11","volume":"509","author":"Buss J.L.","year":"2002","unstructured":"Buss JL, Hermes-Lima M, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues.","journal-title":"Adv Exp Med Biol"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.yjmcc.2005.05.008","volume":"39","author":"Simunek T.","year":"2005","unstructured":"Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, Paulus WJ, Musters RJ. SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.","journal-title":"J Mol Cell Cardiol"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0008-6363(00)00088-2","volume":"47","author":"Horackova M.","year":"2000","unstructured":"Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes.","journal-title":"Cardiovasc Res"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bjp.2008.236","volume":"155","author":"Simunek T.","year":"2008","unstructured":"Simunek T, Sterba M, Popelova O, Kaiserova H, Adamcova M, Hroch M, Haskova P, Ponka P, Gersl V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.","journal-title":"Br J Pharmacol"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tox.2007.03.020","volume":"235","author":"Sterba M.","year":"2007","unstructured":"Sterba M, Popelov\u00e1 O, Sim\u016fnek T, Mazurov\u00e1 Y, Pot\u00e1cov\u00e1 A, Adamcov\u00e1 M, Guncov\u00e1 I, Kaiserov\u00e1 H, Palicka V, Ponka P, Gersl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH).","journal-title":"Toxicology"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1124\/jpet.106.111468","volume":"319","author":"Sterba M.","year":"2006","unstructured":"Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Kaiserova H, Ponka P, Gersl V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/jssc.200500077","volume":"28","author":"Kovarikova P.","year":"2005","unstructured":"Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, Ponka P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an study.","journal-title":"J Sep Sci"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/tx100359t","volume":"24","author":"Hruskova K.","year":"2011","unstructured":"Hruskova K, Kovarikova P, Bendova P, Haskova P, Mackova E, Stariat J, Vavrova A, Vavrova K, Simunek T. Synthesis and initial evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis.","journal-title":"Chem Res Toxicol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejmech.2016.05.015","volume":"120","author":"Hruskova K.","year":"2016","unstructured":"Hruskova K, Potuckova E, Hergeselova T, Liptakova L, Haskova P, Mingas P, Kovarikova P, Simunek T, Vavrova K. Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.","journal-title":"Eur J Med Chem"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s007750050312","volume":"4","author":"Richardson D.R.","year":"1999","unstructured":"Richardson DR, Bernhardt PV. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: An iron chelator with anti-tumour activity.","journal-title":"J Biol Inorg Chem"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/ars.2012.4540","volume":"18","author":"Merlot A.M.","year":"2013","unstructured":"Merlot AM, Kalinowski DS, Richardson DR. Novel chelators for cancer treatment: Where are we now?","journal-title":"Antioxid Redox Signal"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","volume":"57","author":"Kalinowski D.S.","year":"2005","unstructured":"Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer.","journal-title":"Pharmacol Rev"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-011-1587-y","volume":"68","author":"Rao V.A.","year":"2011","unstructured":"Rao VA, Zhang J, Klein SR, Espandiari P, Knapton A, Dickey JS, Herman E, Shacter EB. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jinorgbio.2009.05.007","volume":"103","author":"Hasinoff B.B.","year":"2009","unstructured":"Hasinoff BB, Patel D. The iron chelator Dp44mT does not protect myocytes against doxorubicin.","journal-title":"J Inorg Biochem"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"14901","DOI":"10.1073\/pnas.0604979103","volume":"103","author":"Whitnall M.","year":"2006","unstructured":"Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","volume":"80","author":"Kovacevic Z.","year":"2011","unstructured":"Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer.","journal-title":"Mol Pharmacol"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/jm300768u","volume":"55","author":"Lovejoy D.B.","year":"2012","unstructured":"Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, Basha MT, Sharpe PC, Jansson PJ, Kalinowski DS, Bernhardt PV, Richardson DR. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration","journal-title":"J Med Chem"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"42411","DOI":"10.18632\/oncotarget.6389","volume":"6","author":"Sestak V.","year":"2015","unstructured":"Sestak V, Stariat J, Cermanova J, Potuckova E, Chladek J, Roh J, Bures J, Jansova H, Prusa P, Sterba M, Micuda S, Simunek T, Kalinowski DS, Richardson DR, Kovarikova P. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.","journal-title":"Oncotarget"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jinorgbio.2011.02.003","volume":"105","author":"Mladenka P.","year":"2011","unstructured":"Mladenka P, Macakova K, Filipsky T, Zatloukalova L, Jahodar L, Bovicelli P, Silvestri IP, Hrdina R, Saso L. analysis of iron chelating activity of flavonoids.","journal-title":"J Inorg Biochem"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.freeradbiomed.2010.06.010","volume":"49","author":"Mladenka P.","year":"2010","unstructured":"Mladenka P, Zatloukalova L, Filipsky T, Hrdina R. Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity.","journal-title":"Free Radic Biol Med"},{"key":"ref=120","first-page":"366","volume":"41","author":"Randive K.H.","year":"2015","unstructured":"Randive KH, Jaishree V, Patil KS, Patil K. Synthesis and biological evaluation of novel coumarin derivatives as antioxidant agents.","journal-title":"Bioorg Khim"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.biochi.2010.03.025","volume":"92","author":"Mladenka P.","year":"2010","unstructured":"Mladenka P, Macakova K, Zatloukalova L, Rehakova Z, Singh BK, Prasad AK, Parmar VS, Jahodar L, Hrdina R, Saso L. interactions of coumarins with iron.","journal-title":"Biochimie"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.bmc.2011.11.016","volume":"20","author":"Kathuria A.","year":"2012","unstructured":"Kathuria A, Priya N, Chand K, Singh P, Gupta A, Jalal S, Gupta S, Raj HG, Sharma SK. Substrate specificity of acetoxy derivatives of coumarins and quinolones towards Calreticulin mediated transacetylation: Investigations on antiplatelet function.","journal-title":"Bioorg Med Chem"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1568026615666150206152233","volume":"15","author":"Filipsky T.","year":"2015","unstructured":"Filipsky T, Riha M, Macakova K, Anzenbacherova E, Karlickova J, Mladenka P. Antioxidant effects of coumarins include direct radical scavenging, metal chelation and inhibition of ROS-producing enzymes.","journal-title":"Curr Top Med Chem"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2174\/1568026615666150220112437","volume":"15","author":"Najmanova I.","year":"2015","unstructured":"Najmanova I, Dosedel M, Hrdina R, Anzenbacher P, Filipsky T, Riha M, Mladenka P. Cardiovascular effects of coumarins besides their antioxidant activity.","journal-title":"Curr Top Med Chem"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.nu.15.070195.000521","volume":"15","author":"Lonnerdal B.","year":"1995","unstructured":"Lonnerdal B, Iyer S. Lactoferrin: Molecular structure and biological function.","journal-title":"Annu Rev Nutr"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10534-008-9172-5","volume":"22","author":"Mladenka P.","year":"2009","unstructured":"Mladenka P, Semecky V, Bobrovova Z, Nachtigal P, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Hrdina R. The effects of lactoferrin in a rat model of catecholamine cardiotoxicity.","journal-title":"Biometals"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","volume":"7","author":"Rautio J.","year":"2008","unstructured":"Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. Prodrugs: Design and clinical applications.","journal-title":"Nat Rev Drug Discov"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jinorgbio.2016.05.012","volume":"162","author":"Oliveri V.","year":"2016","unstructured":"Oliveri V, Vecchio G. Prochelator strategies for site-selective activation of metal chelators.","journal-title":"J Inorg Biochem"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1039\/b705199a","volume":"43","author":"Charkoudian L.K.","year":"2007","unstructured":"Charkoudian LK, Pham DM, Kwon AM, Vangeloff AD, Franz KJ. Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress.","journal-title":"Dalton Trans"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1039\/c2mt20069d","volume":"4","author":"Kielar F.","year":"2012","unstructured":"Kielar F, Helsel ME, Wang Q, Franz KJ. Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation.","journal-title":"Metallomics"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jinorgbio.2008.08.001","volume":"102","author":"Charkoudian L.K.","year":"2008","unstructured":"Charkoudian LK, Dentchev T, Lukinova N, Wolkow N, Dunaief JL, Franz KJ. Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide.","journal-title":"J Inorg Biochem"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/jo0015873","volume":"66","author":"Simon J.","year":"2001","unstructured":"Simon J, Salzbrunn S, Prakash GK, Petasis NA, Olah GA. Regioselective conversion of arylboronic acids to phenols and subsequent coupling to symmetrical diaryl ethers.","journal-title":"J Org Chem"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tox.2016.03.004","volume":"350-352","author":"Jansova H.","year":"2016","unstructured":"Jansova H, Bures J, Machacek M, Haskova P, Jirkovska A, Roh J, Wang Q, Franz KJ, Kovarikova P, Simunek T. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.","journal-title":"Toxicology"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpba.2014.11.044","volume":"105","author":"Bure\u0161 J.","year":"2015","unstructured":"Bure\u0161 J, Jansov\u00e1 H, Stariat J, Filipsk\u00fd T, Mlad\u011bnka P, \u0160im\u016fnek T, Ku\u010dera R, Klime\u0161 J, Wang Q, Franz KJ, Kova\u0159\u00edkov\u00e1 P. LC-UV\/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH).","journal-title":"J Pharm Biomed Anal"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"12424","DOI":"10.1021\/ja064806w","volume":"128","author":"Charkoudian L.K.","year":"2006","unstructured":"Charkoudian LK, Pham DM, Franz KJ. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation.","journal-title":"J Am Chem Soc"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-003-0498-7","volume":"130","author":"Swain S.M.","year":"2004","unstructured":"Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF01967305","volume":"26","author":"Hasinoff B.B.","year":"1989","unstructured":"Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.","journal-title":"Agents Actions"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/1471-2407-14-842","volume":"14","author":"Deng S.","year":"2014","unstructured":"Deng S, Yan T, Jendrny C, Nemecek A, Vincetic M, Godtel-Armbrust U, Wojnowski L. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.","journal-title":"BMC Cancer"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"Lyu Y.L.","year":"2007","unstructured":"Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.","journal-title":"Cancer Res"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"e76676","DOI":"10.1371\/journal.pone.0076676","volume":"8","author":"Vavrova A.","year":"2013","unstructured":"Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M, Simunek T. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.","journal-title":"PLoS One"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.yjmcc.2015.12.021","volume":"91","author":"Lencova-Popelova O.","year":"2016","unstructured":"Lencova-Popelova O, Jirkovsky E, Jansova H, Jirkovska-Vavrova A, Vostatkova-Tichotova L, Mazurova Y, Adamcova M, Chladek J, Hroch M, Pokorna Z, Gersl V, Simunek T, Sterba M. Cardioprotective effects of inorganic nitrate\/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.","journal-title":"J Mol Cell Cardiol"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1385\/CT:2:2:111","volume":"2","author":"Hasinoff B.B.","year":"2002","unstructured":"Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.","journal-title":"Cardiovasc Toxicol"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1139\/y2012-009","volume":"90","author":"Zatloukalova L.","year":"2012","unstructured":"Zatloukalova L, Filipsky T, Mladenka P, Semecky V, Macakova K, Holeckova M, Vavrova J, Palicka V, Hrdina R. Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity.","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/155755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T16:38:49Z","timestamp":1606754329000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/155755\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":143,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867324666170920155439","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}